Myriad Pathology Foundation Overview

To give back to the pathology community for its long-standing support of Maixin Company, to enhance innovation and application of pathology technologies, and to promote the in-depth development of pathology work in my country, Fuzhou Maixin launched the Maixin Pathology Fund program in 2009, which has been held for three consecutive years to date. To further motivate researchers and stimulate their creativity, focus on key areas, and concentrate resources to address major problems urgently needing solutions in the field of immunohistochemistry, the Maixin Pathology Fund program will undergo a trial adjustment in 2012, adding a bidding project while retaining the original open-topic projects.
Fund Objectives
To implement the national policy of encouraging innovation, accelerate the pace of national innovation, discover and cultivate outstanding talents, vigorously promote the scientific spirit, give back to the pathology community for its long-term support of Maixin, and promote the development of my country’s pathology cause, scientific and technological progress, and the growth of pathology talents.
Fund Operation Direction
The “Fund” research and development funding is open to pathology disciplines nationwide (bidding projects are open to pathology and related disciplines nationwide), mainly for the research and development of immunohistochemical diagnostic reagents, technological improvements and new reagent applications, as well as research on immunohistochemical standardization and the training of young and middle-aged professionals.
Application Requirements
Applicants must be from institutions with the basic conditions for project research, have been engaged in pathology or related professions for more than five years, and be young and middle-aged professionals below the associate senior level (including associate senior level) engaged in technology and diagnosis. Applicants must have the time and ability to conduct research projects (Note: Open-topic projects are limited to pathology disciplines).
The specific intentions for the 2012 bidding projects are as follows:
1. Research on Immunohistochemical Quality Control and Standards
These projects will focus on supporting research related to promoting immunohistochemical standardization. Leveraging the advantages of hospitals’ abundant disease types and case resources, this encourages pathology-related professionals to actively explore immunohistochemical standardization and quality control, and gradually develop complete quality control methods and procedures that meet current pathology needs. 2. Research on New Monoclonal Antibodies or Domestically Produced Antibodies for Pathological Diagnosis
Monoclonal antibodies are increasingly used in modern pathological diagnosis and are highly favored by the pathology community. However, the sensitivity and specificity of some antibodies still fall short of practical application. Therefore, this project focuses on supporting research on new monoclonal antibodies or domestically produced antibodies that have not yet been officially published in China. It encourages the search for new tumor markers to meet current pathological diagnostic needs, providing technical support for improving pathological diagnostic levels and medical services.
Since its inception, the Maxim Pathology Fund has received strong support and enthusiastic participation from professors in the pathology field. We express our sincere gratitude! The Maxim Pathology Fund Management Committee adheres to the principles of “selecting the best and ensuring fairness and reasonableness” in its review process. Five renowned experts in China will conduct a unified review. Projects will be reviewed through a combination of peer review and review by the Fund’s executive committee. You can obtain the relevant forms by emailing maxim.fund@gmail.com or visiting the Maxim company website. The deadline for submitting applications is October 18, 2012. The review period is from October 25th to November 25th, and the results will be announced in mid-to-late December. We welcome active participation from colleagues in the pathology field!